225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer

Clemens Kratochwil1, Frank Bruchertseifer*2, Frederik L. Giesel1, Mirjam Weis2, Frederik A. Verburg3, Felix Mottaghy3, Klaus Kopka4, Christos Apostolidis2, Uwe Haberkorn1, and Alfred Morgenstern2

1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany; 2European Commission, Joint Research Centre, Institute for Transuranium Elements, Karlsruhe, Germany; 3Department of Nuclear Medicine, RWTH University Hospital Aachen, Aachen, Germany; and 4Division of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany

Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer. Recently, we started the first-in-human treatment with an α-radiocyclode-labeled PSMA ligand. Although the case series is still ongoing, we here report in advance about two patients in highly challenging clinical situations who showed a complete response to 225Ac-PSMA-617 therapy. Methods: 68Ga-PSMA-11 PET/CT validated the presence of the PSMA-positive tumor phenotype. A 100-kBq activity of 225Ac-PSMA-617 per kilogram of body weight was administered bimonthly. Prostate-specific antigen response and hematologic toxicity were measured at least every 4 wk. Restaging was performed with 68Ga-PSMA-11 PET/CT. Results: Both patients experienced a prostate-specific antigen decline to below the measurable level and showed a complete response on imaging. No relevant hematologic toxicity was observed. Xerostomia was the only mentionable clinical side effect. Conclusion: Targeted α-therapy with 225Ac-PSMA-617, although still experimental, obviously has strong potential to significantly benefit advanced-stage prostate cancer patients.

Key Words: PSMA; 225Ac; alpha-therapy

J Nucl Med 2016; 57:1–4
DOI: 10.2967/jnumed.116.178673

A
fter the introduction of prostate-specific membrane antigen targeting 68Ga-labeled PSMA-11 as a new PET tracer for prostate cancer (1), PSMA-617, a ligand with optimized tumor cell internalization and lowered kidney uptake containing the more universal DOTA chelator, was developed for PSMA-targeted radioligand therapy (2,3). For therapy of metastatic castration-resistant prostate cancer (mCRPC), various centers confirmed 177Lu-PSMA-617 to have a favorable dosimetry (4–6) and a convincing response in terms of both serum prostate-specific antigen (PSA) level and radiologic findings (4,7). Nevertheless, about 30% of patients do not respond to 177Lu-labeled PSMA ligands, and despite good tolerability in general, diffuse red marrow infiltration has been suggested as a risk factor for developing relevant hematologic toxicity (4). It has already been demonstrated that targeted α-radiation therapy with 21Bi-DOTATOC could break radioresistance to β-emitters while simultaneously reducing hematologic toxicity in patients with diffuse red marrow infiltration of neuroendocrine tumors (8).

Here, we report our initial experience with targeted 225Ac-PSMA-617 α-therapy in one patient in whom treatment with β-emitters was contraindicated (patient A) and one patient resistant to 177Lu-PSMA-617 (patient B).

MATERIALS AND METHODS

Because these cases concern retrospective reports on findings in regular clinical care but not a systematic clinical trial, ethical approval was not needed. The patients were informed about the experimental nature of this therapy and gave written informed consent to receive it; both agreed to the publication of their individual patient history.

Patients

225Ac-PSMA-617 was offered as salvage therapy in accordance with paragraph 37, “Unproven Interventions in Clinical Practice,” of the updated Declaration of Helsinki and in accordance with German regulations, which include priority of approved treatments and confirmation of the indication by a nuclear medicine physician and an expert in urologic oncology. Patient A presented with diffuse red marrow infiltration of mCRPC, which was considered a contraindication for treatment with β-emitters, and patient B presented with peritoneal carcinomatosis and liver metastases that were progressive under 177Lu-PSMA-617 therapy. Both patients had undergone extensive pretreatment (Table 1).

Radiopharmaceuticals

Good manufacturing practice–grade PSMA-11 and PSMA-617 were obtained from ABX. 225Ac was produced by radiochemical extraction from 229Th (9,10). 68Ga was eluted from a 68Ge/68Ga-generator on site. 177Lu was obtained from ITG. The labeling conditions for 68Ga-PSMA-11 and 177Lu-PSMA-617 have been described previously (4).

For radiolabeling of 225Ac-PSMA-617, an aliquot of 225Ac stock solution was added to a microwave vial containing 0.1 M Tris buffer (pH 9) and an appropriate amount of PSMA-617 stock solution. The reaction mixture was heated to 95°C for 5 min using a microwave synthesizer (Biotage Initiator).

Quality control was performed by instant thin-layer chromatography with 0.05 M citric acid (pH 5) as the solvent. After development, the chromatography strip was stored for at least 1 h until radiochemical equilibrium was obtained between 225Ac (half-life [T1/2], 9.9 d) and its daughter nuclide 218Fr (T1/2, 4.8 min). Subsequently, radiochemical purity was determined by measuring the activity of the 218-keV γ-emission of 225Ac.
221Fr on the upper and lower parts of the strip using high-resolution γ-spectrometry (Ortec). The mean radiochemical purity (±SD) of the radiolabeled peptide was 98.8% ± 0.8% at a specific activity of 0.17 ± 0.05 MBq/nmol.

After synthesis, an aliquot of ascorbic acid was added to the reaction mixture (to minimize radiolytic degradation of 225Ac-PSMA-617) together with an aliquot of diethylenetriaminepentaacetic acid (to scavenge free radiometals). The final pH of the formulation was 7.4. Sterility was ensured via sterile filtration.

Imaging

68Ga-PSMA-11 PET/CT and 177Lu-PSMA-617 emission scans were performed as described previously (1,6).

Posttherapy 225Ac-PSMA-617 scans were acquired using the 440-keV γ-co-emission of 213Bi (26% emission probability), the 218-keV γ-co-emission of 221Fr (12%), and the bremsstrahlung of 209Pb with a scan speed of 10 cm/min on a 2.54-cm-crystal (1-in) γ-camera (Hawkeye; GE Healthcare) equipped with a high-energy collimator.

RESULTS

Clinical Course of Patient A

After exhausting conventional therapies (Table 1), imaging with PSMA PET/CT was suggestive of diffuse red marrow infiltration (Fig. 1A). This was considered a contraindication for 177Lu-PSMA-617 therapy. Therefore, patient A was treated with 3 cycles of 9–10 MBq (100 kBq per kilogram of body weight) of 225Ac-PSMA-617 at bimonthly intervals. Posttherapeutic emission scans validated sufficient tumor targeting (Supplemental Fig. 1; supplemental materials are available at http://jnm.snmjournals.org). Two months later, all previously PSMA-positive lesions had visually disappeared on PSMA PET/CT (Fig. 1B) and, accordingly, the PSA level had dropped from more than 3,000 ng/mL to 0.26 ng/mL. The patient received an additional 6 MBq of 225Ac-PSMA-617 as consolidation therapy, resulting in a further PSA decline to less than 0.1 ng/mL along with a complete imaging response (Fig. 1C).

After each cycle, the blood cell count and alkaline phosphatase level were checked every 2 wk. The platelet level never dropped below 100/nL (grade 1 according to the Common Terminology Criteria for Adverse Events, version 4.0), the total white blood cell count never dropped below 2.5/nL (grade 1), and the hemoglobin level never dropped below 9.5 g/dL (grade 2) (Fig. 2A). Moderate but enduring xerostomia was the only clinically reported side effect. A concordant decline in PSA level and alkaline phosphatase level (Fig. 2B) further underlined the excellent treatment response.

Clinical Course of Patient B

Conventional treatments were also exhausted for patient B, who had peritoneal carcinomatosis and liver infiltration (Fig. 3A) at the time that 177Lu-PSMA-617 (7.4 GBq per cycle) was offered as salvage therapy. The initial PSA level was 294 ng/mL. Despite sufficient tumor targeting as demonstrated by posttherapeutic emission scans (Supplemental Fig. 2), after cycle 2 the PSA level increased to 419 ng/mL and most lesions demonstrated tumor progression on PSMA PET/CT (Fig. 3B). Therapy was changed to...

---

**TABLE 1** Overview of Pretreatments

<table>
<thead>
<tr>
<th>Pretreatment</th>
<th>Patient A</th>
<th>Patient B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leuprorelin</td>
<td>Radical prostatectomy</td>
<td></td>
</tr>
<tr>
<td>Zoledronate</td>
<td>Radiotherapy of lymph node metastasis</td>
<td></td>
</tr>
<tr>
<td>Docetaxel (50 cycles)</td>
<td>Leuprorelin</td>
<td></td>
</tr>
<tr>
<td>Carmustine/epirubicin in hyperthermia</td>
<td>Leuprorelin plus bicalutamide, 150 mg/d</td>
<td></td>
</tr>
<tr>
<td>Abiraterone</td>
<td>Docetaxel (11 cycles)</td>
<td></td>
</tr>
<tr>
<td>Enzalutamide</td>
<td>Cabazitaxel (10 cycles)</td>
<td></td>
</tr>
<tr>
<td>223Ra (6 cycles)</td>
<td>Abiraterone</td>
<td></td>
</tr>
<tr>
<td>Abiraterone reexposition</td>
<td>Enzalutamide (not tolerated)</td>
<td></td>
</tr>
<tr>
<td>Estramustine</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**FIGURE 1.** 68Ga-PSMA-11 PET/CT scans of patient A. Pretherapeutic tumor spread (A), restaging 2 mo after third cycle of 225Ac-PSMA-617 (B), and restaging 2 mo after one additional consolidation therapy (C).

**FIGURE 2.** Laboratory test follow-up of patient A. Arrows indicate administration of treatment cycles. (A) Blood cell count demonstrates moderate hematologic toxicity. (B) Decline of tumor markers to none measurable or reference range correlates with imaging response. AP = alkaline phosphatase; Hb = hemoglobin; PLT = platelets; WBC = white blood cells.
However, spray substitution of saliva had already demonstrated promising results (matologic toxicity; PSA dropped to below the measurable level after 3 cycles (Fig. 3D). Laboratory tests revealed no relevant hematologic toxicity observed after treatment of patient A is reasonable.

DISCUSSION
Here, we present a novel treatment concept for patients with mCRPC that is progressive under conventional therapy or β-emitting 

225Ac-PSMA-617, and the patient received 3 cycles of 6.4 MBq (100 kBq per kilogram of body weight) at bimonthly intervals. Restaging based on the PSMA PET/CT results finally indicated a partial response after 2 cycles (Fig. 3C) and a complete remission after 3 cycles (Fig. 3D). Laboratory tests revealed no relevant hematologic toxicity; PSA dropped to below the measurable level (Fig. 4) (<0.1 ng/mL) (Fig. 4). However, spray substitution of saliva had to be prescribed after the last cycle because of severe xerostomia.

FIGURE 3. 

FIGURE 4. Laboratory test follow-up of patient B. Arrows indicate administration of treatment cycles. Blood cell count (A) always stayed in reference range, and tumor marker PSA (B) finally declined to none measurable.

225Ac-PSMA-617 Prostate Cancer Therapy • Kratochwil et al.
solved before large studies are feasible. However, several methods of accelerator-driven production of $^{225}$Ac have already been described (16,17), and routine production of this radionuclide can be realized with manageable effort once a relevant demand is predictable. Our early results already indicate that $^{225}$Ac-targeted $\alpha$-therapy has high potential for the epidemiologically important tumor entity prostate cancer, which presumably will further accelerate the routine availability of $^{225}$Ac for systematic clinical trials, for example.

CONCLUSION

The two impressive responses reported here demonstrate the high potential of $^{225}$Ac-PSMA-617 to significantly benefit mCRPC patients who are in a clinically critical situation, that is, patients with diffuse red marrow infiltration and resistance to other therapies. Investigation of this therapeutic modality in larger patient cohorts is warranted.

DISCLOSURE

The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734. A patent application for PSMA-617 (regardless of the radiolabeling nuclide) was submitted by Drs. Kopka and Haberkorn. No other potential conflict of interest relevant to this article was reported.

REFERENCES

225Ac-PSMA-617 for PSMA targeting alpha-radiation therapy of patients with metastatic castration-resistant prostate cancer

Clemens Kratochwil, Frank Bruchertseifer, Frederik L Giesel, Mirjam Weis, Frederik A Verburg, Felix Mottaghy, Klaus Kopka, Christos Apostolidis, Uwe Haberkorn and Alfred Morgenstern

J Nucl Med.
Published online: July 7, 2016.
Doi: 10.2967/jnumed.116.178673

This article and updated information are available at:
http://jnm.snmjournals.org/content/early/2016/07/27/jnumed.116.178673

Information about reproducing figures, tables, or other portions of this article can be found online at:
http://jnm.snmjournals.org/site/misc/permission.xhtml

Information about subscriptions to JNM can be found at:
http://jnm.snmjournals.org/site/subscriptions/online.xhtml

JNM ahead of print articles have been peer reviewed and accepted for publication in JNM. They have not been copyedited, nor have they appeared in a print or online issue of the journal. Once the accepted manuscripts appear in the JNM ahead of print area, they will be prepared for print and online publication, which includes copyediting, typesetting, proofreading, and author review. This process may lead to differences between the accepted version of the manuscript and the final, published version.